Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001011438-25-000122
Filing Date
2025-02-13
Accepted
2025-02-13 18:17:52
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 9094
  Complete submission text file 0001011438-25-000122.txt   11041
Mailing Address 9713 KEY WEST AVENUE, SUITE 400 ROCKVILLE MD 20850
Business Address 9713 KEY WEST AVENUE, SUITE 400 ROCKVILLE MD 20850 301-517-5556
MAXCYTE, INC. (Subject) CIK: 0001287098 (see all company filings)

EIN.: 522210438 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-92738 | Film No.: 25622170
SIC: 8731 Services-Commercial Physical & Biological Research
(CF Office: 08 Industrial Applications and Services)

Mailing Address 535 MADISON AVENUE, 36TH FLOOR NEW YORK NY 10022
Business Address 535 MADISON AVENUE, 36TH FLOOR NEW YORK NY 10022 212-792-8800
CADIAN CAPITAL MANAGEMENT, LP (Filed by) CIK: 0001423686 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A